The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...

A doctor from the University of Palermo in Italy has published a case study of an adult cocaine user who experienced reduced ...

Tirzepatide is just as effective in reducing cardiovascular risk driven by central adiposity as that driven by general ...

Many of these unlawful and unauthorized shipments were explicitly tagged for compounding, which in turn could put many ...

Novo Nordisk's (NVO) weight loss therapy Wegovy/Ozempic come out of shortage, but the FDA won't crack down on compounders ...

A new clinical trial showed promising results in curbing alcohol cravings in individuals with moderate alcohol-use disorder.

Jacobs Solutions CEO Bob Pragada joins 'Squawk Box' to discuss the building opportunities of life science facilities to meet ...

Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...

As GLP-1 medications such as Ozempic, Mounjaro and Wegovy rise in popularity, so do concerns over their side effects.

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

This article showcases a curated list of standout studies over the last week on topics such as cholesterol, GLP-1 drugs for ...

ORLANDO, FLA. — Increasing levels of protein and fiber, stressing portion control, and adding savory flavors are ways that ...